Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Proteins and Peptides in Tears Indicate Eye Conditions

By LabMedica International staff writers
Posted on 30 Apr 2013
Diseases such as dry eye and blepharitis (inflammation of the eyelids) change the proportions of certain proteins in normal tears.

A new test to diagnose dry eye would be especially useful because it is currently diagnosed by interview backed up by tests, which are not particularly reproducible.

Tatiana Suarez from Bioftalmik (Derio, Spain) and colleagues in Spain undertook a proteomics study using 2D PAGE to identify any potential protein biomarkers before carrying out a detailed validation study of the candidate species.

One hundred and forty-four participants were enrolled in the study, comprising 63 with dry eye, 38 with MGD and 43 healthy controls. More...
Tears were collected from 44 patients using surgical sponges, 16 with each disease, and 12 controls. The abundant protein immunoglobulin A was removed by immunoaffinity chromatography in case it swamped the less abundant proteins.

The remaining proteins were separated by 2D electrophoresis (PAGE) and their positions on the gel were identified by staining with a fluorescent dye. A total of 130 protein spots were resolved and image analysis was conducted to pinpoint the proteins which had different abundances between the three groups and these were identified by mass spectrometry.

Before refining the panel of proteins to a more manageable number that retained the predictive capability, they were screened by enzyme-linked immuno sorbent assay (ELISA) to identify the most predictive ones. Two validations steps followed in which the proteins were collected by sponge or capillary. The best classification method was achieved with the Random Forest and Naïve Bayes machine learning techniques which were trained using one set of results and confirmed on the others.

A network analysis of the 15 discriminatory proteins revealed that nine of them were directly or indirectly related. The major biological processes in which they are involved include inflammatory response, stress response, immune response, and oxidative stress response.

The final discriminatory panel obtained after refinement of the model consisted of five proteins: S100A6, annexin A1, annexin A11, cystatin-S and phospholipase A2-activating protein. Together they were able to discriminate between dry eye and control patients with high sensitivity and specificity. They could also distinguish between the dry eye, MGD, and control groups with good accuracy. The results were independent of the tear collection method.

The team will examine the biomarkers in a clinical setting and possibly develop a test for dry eye and meibomian gland dysfunction.

Related Links:
Bioftalmik




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.